Results 1 to 10 of about 29,549 (204)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations [PDF]

JTO Clinical and Research Reports, 2021
Introduction: In this study, we sought to further characterize ROS1 protein expression in solid tumors with the complete spectrum of ROS1 genomic alterations. Methods: ROS1 immunohistochemistry (IHC) was performed using the ROS1 (SP384) class I assay per
Richard S.P. Huang, MD, Amanda Gottberg-Williams, BS, Panhia Vang, BS, Shoua Yang, HSD, Nicholas Britt, BS, Jaspreet Kaur, MS, James Haberberger, BS, Natalie Danziger, BS, Clarence Owens, BS, Sara E. Beckloff, PhD, Jeffrey S. Ross, MD, Shakti H. Ramkissoon, MD, PhD   +11 more
doaj   +3 more sources

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib [PDF]

Frontiers in Medicine, 2021
ROS1 rearrangement, identified in ~2% of non-small cell lung cancer (NSCLC), has defined a distinctive molecular subtype. Patients with ROS1 fusion have been shown to be highly sensitive to treatment with crizotinib.
Long Xu, Xiaoxia Chen, Hong Huo, Yongye Liu, Xiaodan Yang, Dejian Gu, Mingming Yuan, Min Zhang, Min Zhang, Rongrong Chen, Jiayin Wang, Zhendong Zheng   +11 more
doaj   +3 more sources

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report

Case Reports in Oncology, 2023
Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ...
Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, Toshiki Ikeda, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Koki Maeda, Tsuneo Shimokawa, Hiroaki Okamoto   +12 more
doaj   +1 more source

OPRM1-ROS1 Fusion Detected by Next-Generation Sequencing with Circulating DNA in a Patient with EGFR Mutated Advanced NSCLC: A Case Report

Case Reports in Oncology, 2022
ROS1 comprises a small molecular subset of NSCLC, and several fusion partners have been discovered. Concomitant mutations of EGFR and ROS1 in NSCLC have been occasionally reported, while no clear standard of treatment has been revealed.
Sicai Zhang, Zhiyong Xu, Weimin Zhang
doaj   +1 more source

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Drugs in Context, 2022
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is
Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter   +4 more
doaj   +1 more source

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China

Frontiers in Cell and Developmental Biology, 2022
Objective: This study aimed to identify ROS1 fusion partners in Chinese patients with solid tumors.Methods: Next-generation sequencing (NGS) analysis was used to detect ROS1 rearrangement in 45,438 Chinese patients with solid tumors between 2015 and 2020,
Ning Li, Zhiqin Chen, Mei Huang, Ding Zhang, Mengna Hu, Feng Jiao, Ming Quan   +6 more
doaj   +1 more source

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma

JTO Clinical and Research Reports, 2023
Introduction: Translocations of the ROS1 gene were found to drive tumorigenesis in 1% to 2% of lung adenocarcinoma. In clinical practice, ROS1 rearrangements are often screened by immunohistochemistry (IHC) before confirmation with either fluorescence in
Karl Grenier, MD, PhD, Jean-Baptiste Rivière, PhD, Bouchra Ouled Amar Bencheikh, PhD, Andrea Liliam Gomez Corredor, PhD, Benjamin Christopher Shieh, MD, Hangjun Wang, MD, Pierre Olivier Fiset, MD, PhD, Sophie Camilleri-Broët, MD, PhD   +7 more
doaj   +1 more source

ROS1 in non-small-cell lung carcinoma: A narrative review

Cancer Research, Statistics, and Treatment, 2022
ROS1 rearranged non-small-cell lung cancer (NSCLC) is a distinct molecular subtype of NSCLC, accounting for 2% of cases. Typically, these are genomic rearrangements resulting in a fusion oncoprotein that causes unabated constitutive signaling.
Shrinidhi Nathany, Ullas Batra, Rashi Sachdeva, Mansi Sharma, B P Amrith, Shriya Vaidya   +5 more
doaj   +1 more source

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

BMC Cancer, 2023
Background Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence of ROS1 fusions to assess if more ROS1+ patients who could ...
Misako Nagasaka, Shannon S. Zhang, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Luis E. Raez, Stephen V. Liu, Sai-Hong Ignatius Ou   +11 more
doaj   +1 more source

Methylation-Sensitive Expression of a DNA Demethylase Gene Serves As an Epigenetic Rheostat [PDF]

, 2014
Genomes must balance active suppression of transposable elements (TEs) with the need to maintain gene expression. In Arabidopsis, euchromatic TEs are targeted by RNA-directed DNA methylation (RdDM).
Gehring, Mary, Henikoff, Steven, Pignatta, Daniela, Williams, Ben P.   +3 more
core   +7 more sources